168 related articles for article (PubMed ID: 36334104)
1. [
Lezaic L; Erba PA; Decristoforo C; Zaletel K; Mikolajczak R; Maecke H; Maina T; Konijnenberg M; Kolenc P; Trofimiuk-Müldner M; Przybylik-Mazurek E; Virgolini I; de Jong M; Fröberg AC; Rangger C; Di Santo G; Skorkiewicz K; Garnuszek P; Solnica B; Nock BA; Fedak D; Gaweda P; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):892-907. PubMed ID: 36334104
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients.
Maina T; Konijnenberg MW; KolencPeitl P; Garnuszek P; Nock BA; Kaloudi A; Kroselj M; Zaletel K; Maecke H; Mansi R; Erba P; von Guggenberg E; Hubalewska-Dydejczyk A; Mikolajczak R; Decristoforo C
Eur J Pharm Sci; 2016 Aug; 91():236-42. PubMed ID: 27185299
[TBL] [Abstract][Full Text] [Related]
3. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.
Pawlak D; Rangger C; Kolenc Peitl P; Garnuszek P; Maurin M; Ihli L; Kroselj M; Maina T; Maecke H; Erba P; Kremser L; Hubalewska-Dydejczyk A; Mikołajczak R; Decristoforo C
Eur J Pharm Sci; 2016 Mar; 85():1-9. PubMed ID: 26826279
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin 2 Receptor Agonist
Rottenburger C; Nicolas GP; McDougall L; Kaul F; Cachovan M; Vija AH; Schibli R; Geistlich S; Schumann A; Rau T; Glatz K; Behe M; Christ ER; Wild D
J Nucl Med; 2020 Apr; 61(4):520-526. PubMed ID: 31519804
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
7. Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers.
Corlett A; Pinson JA; Rahimi MN; Zuylekom JV; Cullinane C; Blyth B; Thompson PE; Hutton CA; Roselt PD; Haskali MB
J Med Chem; 2023 Aug; 66(15):10289-10303. PubMed ID: 37493526
[TBL] [Abstract][Full Text] [Related]
8. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
9. Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.
Lipiński PFJ; Garnuszek P; Maurin M; Stoll R; Metzler-Nolte N; Wodyński A; Dobrowolski JC; Dudek MK; Orzełowska M; Mikołajczak R
EJNMMI Res; 2018 Apr; 8(1):33. PubMed ID: 29663167
[TBL] [Abstract][Full Text] [Related]
10. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y.
Maurin M; Garnuszek P; Baran P; Pawlak D; Mikołajczak R
Nucl Med Rev Cent East Eur; 2015; 18(2):51-5. PubMed ID: 26315862
[TBL] [Abstract][Full Text] [Related]
11. [The use of a new analogue DGlu-Octagastrin in scintigraphy of medullary thyroid carcinoma].
Kosowicz J; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Endokrynol Pol; 2006; 57(4):427-30. PubMed ID: 17006848
[TBL] [Abstract][Full Text] [Related]
12. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
13. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
15. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin.
Behr TM; Jenner N; Radetzky S; Béhe M; Gratz S; Yücekent S; Raue F; Becker W
Eur J Nucl Med; 1998 Apr; 25(4):424-30. PubMed ID: 9553173
[TBL] [Abstract][Full Text] [Related]
16. A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.
Erba PA; Maecke H; Mikolajczak R; Decristoforo C; Zaletel K; Maina-Nock T; Peitl PK; Garnuszek P; Froberg A; Goebel G; de Jong M; Jabrocka-Hybel A; Konijnenberg M; Virgolini I; Nock B; Lenda-Tracz W; Pawlak D; Rangger C; Trofimiuk-Müldner M; Sowa-Staszczak A; Tomaszuk M; von Guggenberg E; Scarpa L; Hubalewska-Dydejczyk A
Pol Arch Intern Med; 2018 Dec; 128(12):791-795. PubMed ID: 30516761
[No Abstract] [Full Text] [Related]
17. Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.
Aloj L; Aurilio M; Rinaldi V; D'ambrosio L; Tesauro D; Peitl PK; Maina T; Mansi R; von Guggenberg E; Joosten L; Sosabowski JK; Breeman WA; De Blois E; Koelewijn S; Melis M; Waser B; Beetschen K; Reubi JC; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1417-25. PubMed ID: 21523391
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.
Fröberg AC; de Jong M; Nock BA; Breeman WA; Erion JL; Maina T; Verdijsseldonck M; de Herder WW; van der Lugt A; Kooij PP; Krenning EP
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1265-72. PubMed ID: 19266197
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.
Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M
Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers.
Wayua C; Low PS
J Nucl Med; 2015 Jan; 56(1):113-9. PubMed ID: 25500824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
